Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3 as prophylaxis to reduce the incidence of acute gastroenteritis and upper respiratory tract infections in children
BACKGROUND: For healthy children, attending communities such as nurseries, kindergartens or schools, exposes them to the risk of acute gastroenteritis (AGE) and/or upper respiratory tract infections (URTIs). We therefore evaluated whether the use of a well-documented probiotic formula could act as prophylaxis for AGE and URTIs, reducing the risk of occurrence.
METHODS: In a randomized study, we tested a probiotic mixture containing Bifidobacterium animalis subspecies lactis BB-12 and Enterococcus faecium L3 on 94 healthy children, comparing the incidence and duration of episodes of AGE and the incidence of URTIs to those of a control group of 109 healthy, untreated subjects. In a subgroup consisting of 34 healthy, treated children, we also evaluated salivary IgA levels.
RESULTS: The use of the probiotic formula significantly reduced the incidence and duration of episodes of AGE by 82% and 45%, respectively, and the incidence and duration of episodes of URTIs by 84% and 50%. Salivary IgA levels significantly increased three-fold after 90 days of probiotic treatment. The probiotic formula was well tolerated and no side effects occurred.
CONCLUSIONS: According to our results, use of the probiotic strains BB-12 and L3 statistically reduced the risk of AGE and URTIs in healthy children and increased levels of salivary IgA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Minerva pediatrics - 73(2021), 3 vom: 08. Juni, Seite 222-229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DI Pierro, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulin A, Secretory |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 13.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.23736/S2724-5276.20.05925-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310864011 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310864011 | ||
| 003 | DE-627 | ||
| 005 | 20231225141022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23736/S2724-5276.20.05925-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310864011 | ||
| 035 | |a (NLM)32506882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a DI Pierro, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of a probiotic mixture containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3 as prophylaxis to reduce the incidence of acute gastroenteritis and upper respiratory tract infections in children |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 13.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: For healthy children, attending communities such as nurseries, kindergartens or schools, exposes them to the risk of acute gastroenteritis (AGE) and/or upper respiratory tract infections (URTIs). We therefore evaluated whether the use of a well-documented probiotic formula could act as prophylaxis for AGE and URTIs, reducing the risk of occurrence | ||
| 520 | |a METHODS: In a randomized study, we tested a probiotic mixture containing Bifidobacterium animalis subspecies lactis BB-12 and Enterococcus faecium L3 on 94 healthy children, comparing the incidence and duration of episodes of AGE and the incidence of URTIs to those of a control group of 109 healthy, untreated subjects. In a subgroup consisting of 34 healthy, treated children, we also evaluated salivary IgA levels | ||
| 520 | |a RESULTS: The use of the probiotic formula significantly reduced the incidence and duration of episodes of AGE by 82% and 45%, respectively, and the incidence and duration of episodes of URTIs by 84% and 50%. Salivary IgA levels significantly increased three-fold after 90 days of probiotic treatment. The probiotic formula was well tolerated and no side effects occurred | ||
| 520 | |a CONCLUSIONS: According to our results, use of the probiotic strains BB-12 and L3 statistically reduced the risk of AGE and URTIs in healthy children and increased levels of salivary IgA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Immunoglobulin A, Secretory |2 NLM | |
| 700 | 1 | |a Lo Russo, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Danza, Maria L |e verfasserin |4 aut | |
| 700 | 1 | |a Basile, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Soardo, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Capocasale, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Paparone, Sandro B |e verfasserin |4 aut | |
| 700 | 1 | |a Paletta, Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Lanza, Cosimo |e verfasserin |4 aut | |
| 700 | 1 | |a Schiavone, Elvira |e verfasserin |4 aut | |
| 700 | 1 | |a Risso, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Minerva pediatrics |d 2021 |g 73(2021), 3 vom: 08. Juni, Seite 222-229 |w (DE-627)NLM252826922 |x 2724-5780 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:3 |g day:08 |g month:06 |g pages:222-229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.23736/S2724-5276.20.05925-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 3 |b 08 |c 06 |h 222-229 | ||